Comparison · NCT03897036-sae
Treatment-Duration-Increment vs Expansion: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Treatment-Duration-Increment vs Expansion: serious adverse events. Trial comparisons, record NCT03897036-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03897036-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.25 | 0.0715 | 0.591 | wilson | |
| Risk in group 2 | 0.176 | 0.0619 | 0.41 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0735 | -0.221 | 0.433 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.42 | 0.292 | 6.87 | log | |
| Odds ratio, group 1 over group 2 | 1.56 | 0.205 | 11.8 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Treatment-Duration-Increment than on Expansion | 13.6 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Treatment-Duration-Increment | 1000 mg BID × 28 days/cycle~CX-4945: API powder-in-capsule in 200 mg strength | 2 | 8 | EG000 |
| Group 2 | Expansion | 1000 mg BID × 28 days/cycle~CX-4945: API powder-in-capsule in 200 mg strength | 3 | 17 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Adverse events data were collected After informed consent, but prior to initiation of study drug, only SAEs caused by a protocol-mandated intervention will be collected (e.g., SAEs related to invasive procedures such as biopsies, medication washout, or no treatment run-in). After initiation of study drug, all AEs and SAEs regardless of attribution will be collected until 30 days following the last administration of study treatment or study discontinuation/termination, whichever is later.
Source ClinicalTrials.gov
Trial
- Title
- Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)
- NCT number
- NCT03897036
- Phases
- PHASE1
- Conditions
- Carcinoma, Basal Cell
- Interventions
- CX-4945
- Lead sponsor
- Senhwa Biosciences, Inc.
- Results first posted
- 2025-05-20
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03897036?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03897036-sae